Tuesday, 2 February 2010
Galenica Group’s pharma company Vifor Pharma has signed an agreement with Evotec AG for the development of a preclinical candidate in the field of anaemia. Evotec is a leader in the research and development of novel small molecule drugs. This cooperation supports Vifor Pharma’s long-term strategy to research and develop new drugs for the treatment of anaemia.
_Vifor Pharma has mandated Evotec to provide integrated biology, chemistry and preclinical development as well as project management services for the discovery activities to identify a preclinical candidate for the treatment of anaemia. The project cost is approximately CHF 8.5 million. The agreement applies Evotec’s integrated drug discovery expertise and technologies to proceed from novel small molecules to chemical optimisation of the leads into drug candidates. For confidentiality reasons both companies have agreed that no further details about the research project will be revealed.
_Vifor Pharma has a leading position in the global market for iron replacement therapy. This agreement is consistent with Vifor Pharma’s long-term strategy in anaemia in order to expand its product pipeline by further research and development activities.
_“We have a high regard for Evotec's drug discovery and development expertise and the capabilities and technologies they will use to progress our project. They have a proven expertise in drug discovery and development and we look forward to achieving success with Evotec” said Dr David Ebsworth, CEO at Vifor Pharma.
_Dr Werner Lanthaler, CEO of Evotec, commented: “This agreement represents a great step forward in our business model, as we are committed to identifying a preclinical candidate within an agreed budget. This will allow us to fully integrate and leverage all of our research sites and scientists to efficiently deliver a preclinical candidate to Vifor Pharma and clearly demonstrates the complete
integrated drug discovery capability we have.”
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Wednesday, 1 December 2010
Tuesday, 28 September 2010
Friday, 17 September 2010
Tuesday, 17 August 2010